Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 3,459 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Oral Placebo Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity

NCT02576288
View directory record Official record
Conditions
Atherosclerosis, Inflammation
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

NCT03969888
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ABBV-3067, Placebo ABBV-3067, ABBV-2222, Placebo ABBV-2222
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Tampa, Florida • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

NCT02511886
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Arbaclofen Placarbil, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Oakland Park, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

NCT03033069
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Brexpiprazole, Sertraline, Brexpiprazole Matching Placebo, Sertraline Matching Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
54
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Maralixibat, Volixibat
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
View directory record Official record
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Active, not recruiting Phase 2 Interventional

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

NCT04685590
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Dasatinib + Quercetin, Placebo Capsules
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Fenebrutinib, Teriflunomide, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

NCT07225517
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB145, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Trial of Linaclotide in Patients With Chronic Idiopathic Constipation

NCT02291679
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
95
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

NCT03852446
View directory record Official record
Conditions
Healthy
Interventions
Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia

NCT01980888
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Idelalisib, Bendamustine, Rituximab, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Fullerton, California • La Jolla, California • Santa Maria, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol

NCT04662073
View directory record Official record
Conditions
Covid19
Interventions
Camostat, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Pleasanton, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional

Green Tea Extract: a Non-Surgical Alternative for Treatment of Uterine Fibroids

NCT01311869
View directory record Official record
Conditions
Leiomyoma
Interventions
EGCG ( Green Tea extract), Brown rice pills
Dietary Supplement
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer

NCT02120417
View directory record Official record
Conditions
Breast Cancer
Interventions
Ruxolitinib, Capecitabine, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
80
States / cities
Birmingham, Alabama • Chandler, Arizona • Sedona, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Lebrikizumab, Pirfenidone, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

Safety of Ramelteon in Subjects With Mild to Moderate Obstructive Sleep Apnea

NCT00672061
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Ramelteon or Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
21 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
Birmingham, Alabama • Palm Springs, California • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients

NCT01820442
View directory record Official record
Conditions
Opioid Dependence, Buprenorphine Withdrawal Syndrome
Interventions
Lofexidine HCl, Lofexidine-matching sugar pill
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2Phase 3 Interventional

AMX0035 and Progressive Supranuclear Palsy

NCT06122662
View directory record Official record
Conditions
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
Interventions
AMX0035, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Not applicable Interventional

Galectin-3 Blockade in Patients With High Blood Pressure

NCT01960946
View directory record Official record
Conditions
Hypertension
Interventions
Modified Citrus Pectin (MCP) vs placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 17, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia

NCT05654870
View directory record Official record
Conditions
Schizophrenia
Interventions
Valbenazine, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
13 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
San Jose, California • Coral Gables, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

SPI-1005 Treatment in Severe COVID-19 Patients

NCT04483973
View directory record Official record
Conditions
Covid19, Coronavirus, Coronavirus Infection, Corona Virus Infection
Interventions
Ebselen, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
New Haven, Connecticut • Boise, Idaho • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 17, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT04985942
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Phoenix, Arizona • Glendale, California • Oceanside, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 3:32 AM EDT